Top Markets
#1 Gama Token Gama Token +9.13%
#2 Casper Network Casper Network +6.29%
#3 Berachain Berachain +4.11%
#4 Perle Perle +4.10%
#5 Cross Cross +3.98%
#6 Holoworld Holoworld +3.25%
#7 Venom Venom +3.12%
#8 Tutorial Tutorial +3.07%
#9 The Innovation Game The Innovation Game +3.01%
#10 Velvet Velvet +2.84%
Coin of the day
Gama Token Gama Token
Settings
Language
ENGLISH
Currency
USD
Theme
Guard Therapeutics International AB (publ) Guard Therapeutics International AB (publ)

Guard Therapeutics International AB (publ)

GUARD
Rank in Stocks #36113
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company... Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Share Price
$0.14966934
Last synced: 2026-08-14
Market Cap
$3.02M
Change (1 day)
3.72%
Change (1 year)
-93.70%
Country
SE
Trade Guard Therapeutics International AB (publ) (GUARD)

Category

Healthcare
P/E ratio for Guard Therapeutics International AB (publ) (GUARD)
P/E ratio as of 2026 TTM: 0
According to Guard Therapeutics International AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Guard Therapeutics International AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.